新诊断与复发难治多发性骨髓瘤中细胞遗传学异常共存与高危疾病的关联
该系统综述纳入24项随机对照试验共13926例多发性骨髓瘤患者,采用统一算法进行联邦分析,评估高危细胞遗传学异常(HRCA)共存与预后的关联。结果显示≥两个HRCA患者无进展生存期HR为2.28(95%CI 2.05-2.54),总生存期HR为2.94(95%CI 2.49-3.47);一个HRCA患者无进展生存期HR为1.51(95%CI 1.38-1.65),总生存期HR为1.69(95%CI 1.52-1.88)。2015年后启动的研究中该效应持续存在,且在新诊断和复发难治患者中均一致。
要点
- ≥两个HRCA患者无进展生存期HR为2.28(95%CI 2.05-2.54),总生存期HR为2.94(95%CI 2.49-3.47)。
- 一个HRCA患者无进展生存期HR为1.51(95%CI 1.38-1.65),总生存期HR为1.69(95%CI 1.52-1.88)。
- 2015年后启动的研究中,≥两个HRCA的无进展生存期HR为2.39(95%CI 1.96-2.91),总生存期HR为3.10(95%CI 2.10-4.60)。
核心结论
- ≥两个HRCA与新诊断和复发难治多发性骨髓瘤患者最差预后相关,且该关联在不同治疗模式下均存在。
研究设计与样本
- 系统综述纳入2000年1月1日至2021年12月9日发表的报告HRCA检测的随机对照试验,共24项试验、13926例患者。
- 各组被联系并要求使用中央提供的算法对单打击(一个HRCA)和双打击(≥两个HRCA)进行本地联邦分析,结果集中整理后采用随机效应模型进行荟萃分析。
主要发现
- 患者中位年龄66.5岁(IQR 59-72),男性占56.5%(IQR 52-60)。
- ≥两个HRCA患者无进展生存期HR为2.28(95%CI 2.05-2.54),一个HRCA患者为1.51(95%CI 1.38-1.65)。
- ≥两个HRCA患者总生存期HR为2.94(95%CI 2.49-3.47),一个HRCA患者为1.69(95%CI 1.52-1.88)。
- 2015年后启动的研究中,≥两个HRCA的无进展生存期HR为2.39(95%CI 1.96-2.91),总生存期HR为3.10(95%CI 2.10-4.60),在新诊断和复发难治患者中均如此。
- 异质性涉及移植资格和复发难治状态,与预期一致。
局限性
- 异质性涉及移植资格和复发难治状态,与预期一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Survival for patients with multiple myeloma (MM) has improved but outcomes remain heterogeneous. Consistent diagnostic identification of high-risk disease is desirable to address unmet patient need. The aim was to investigate the consistency of association of co-occurrence of high-risk cytogenetic abnormalities (HRCAs) with prognosis in patients with newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM), and across a range of treatment modalities. METHODS: A systematic review of randomized controlled trials of MM that reported testing for HRCA between January 1, 2000, and December 9, 2021, was performed. Groups were contacted and asked to locally perform a novel, federated analysis of their data for single hit (one HRCA) and double hit (≥two HRCAs), using a centrally provided algorithm. Analysis results were centrally collated and meta-analyzed to assess the hazard ratio (HR) for progression-free survival (PFS) and overall survival (OS) for one/≥two HRCAs across patient subgroups using random-effects models. RESULTS: Twenty-four trials including 13,926 patients were included. The median age of participants was 66.5 years (IQR, 59-72) and 56.5% were male (IQR, 52-60). The HR for PFS was 2.28 (95% CI, 2.05 to 2.54) for patients with ≥two HRCAs and 1.51 (95% CI, 1.38 to 1.65) for patients with one HRCA. The HR for OS was 2.94 (95% CI, 2.49 to 3.47) and 1.69 (95% CI, 1.52 to 1.88) for the two subgroups, respectively. In studies initiated since 2015, the effect abides (≥two HRCA PFS, HR, 2.39 [95% CI, 1.96 to 2.91]; OS, 3.10 [95% CI, 2.10 to 4.60]) both for NDMM and RRMM. Heterogeneity related to transplant eligibility and relapsed/refractory status was as expected. CONCLUSION: The association of ≥two HRCAs with the poorest outcome in NDMM and RRMM, and across treatment modalities, as demonstrated here for the first time to our knowledge, allows for more focused development of novel approaches to these patients with high unmet need.
引用
- Kaiser MF, Sonneveld P, Cairns DA, et al. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025. PMID: 39965171. doi:10.1200/JCO-24-01253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。